Treatment of spinal rhabdomyosarcoma in adults: A case report and literature review of current evidence

Du,Suiyong; Hu,Panpan; Zhuang,Hongqing; Yang,Shaomin; Wei,Feng

doi:10.3892/ol.2023.13685

Treatment of spinal rhabdomyosarcoma in adults: A case report and literature review of current evidence

Authors:
- Suiyong Du
- Panpan Hu
- Hongqing Zhuang
- Shaomin Yang
- Feng Wei
View Affiliations

Affiliations: Department of Orthopaedics, Peking University Third Hospital, Beijing 100191, P.R. China, Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, P.R. China, Department of Pathology, Peking University Third Hospital, Beijing 100191, P.R. China
Published online on: January 30, 2023 https://doi.org/10.3892/ol.2023.13685
Article Number: 99
Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Spinal rhabdomyosarcoma (RMS) is a rare yet highly malignant tumor in adults. Literature on this entity is lacking and no mature treatment guideline is currently available. The treatment arsenals include surgery, radiotherapy and chemotherapy, being used singly or jointly. However, the prognosis is dismal, with a mean overall survival period of 10 months. Thus, any case of this disease with encouraging outcomes shall be shared. A case of a middle‑aged female patient with spinal RMS was presented in the current report. The patient suffered from back pain but was neurologically intact. The patient underwent a total en‑bloc spondylectomy of the T11‑L2 vertebrae and spinal reconstruction with 3D‑printed prosthetic vertebrae. Afterwards, the patient received a rigid schedule of stereotactic body radiotherapy (SBRT) and chemotherapy. To date, the patient has survived for 40 months, with the preservation of neurological function and sustained mitigation of local pain after the operation. The patient suffered subcutaneous colonization of tumor cells and pulmonary metastasis 10 months postoperatively, but obtained a long locoregional control of 19 months. In conclusion, total en‑bloc lesion resection is indicated for the treatment of isolated, primary spinal RMS in adults. Some authors reported that the usage of new surgical tools and instruments has facilitated surgery, which was previously invasive and technically challenging. Advanced radiotherapy techniques, such as SBRT, which were proven effective for local lesion control, should be implemented early after the operation. Chemotherapy remains the mainstay of treatment, but further research and evidence for the efficacy of regimens specifically for adults are required.

View Figures

View References

1	Bompas E, Campion L, Italiano A, Le Cesne A, Chevreau C, Isambert N, Toulmonde M, Mir O, Ray-Coquard I, Piperno-Neumann S, et al: Outcome of 449 adult patients with rhabdomyosarcoma: An observational ambispective nationwide study. Cancer Med. 7:4023–4035. 2018. View Article : Google Scholar : PubMed/NCBI
2	Kaseb H, Kuhn J and Babiker HM: Rhabdomyosarcoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2022.
3	Wang T, Gao X, Yang J, Guo W, Wu Z, Tang L, Cao S, Cai X, Liu T, Jia Q and Xiao J: Treatment strategies and outcomes for spinal rhabdomyosarcoma: A series of 11 cases in a single center and review of the literature. Clin Neurol Neurosurg. 192:1057292020. View Article : Google Scholar : PubMed/NCBI
4	Gurria JP and Dasgupta R: Rhabdomyosarcoma and extraosseous ewing sarcoma. Children (Basel). 5:1652018.PubMed/NCBI
5	Raney RB, Maurer HM, Anderson JR, Andrassy RJ, Donaldson SS, Qualman SJ, Wharam MD, Wiener ES and Crist WM: The intergroup rhabdomyosarcoma study group (IRSG): Major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma. 5:9–15. 2001. View Article : Google Scholar : PubMed/NCBI
6	Spreafico F, Ferrari A, Mascarin M, Collini P, Morosi C, Biasoni D, Biassoni V, Schiavello E, Gandola L, Gattuso G, et al: Wilms tumor, medulloblastoma, and rhabdomyosarcoma in adult patients: lessons learned from the pediatric experience. Cancer Metastasis Rev. 38:683–694. 2019. View Article : Google Scholar : PubMed/NCBI
7	Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C and Ferrari A: Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: An analysis of 2,600 patients. J Clin Oncol. 27:3391–3397. 2009. View Article : Google Scholar : PubMed/NCBI
8	Wei F, Li Z, Liu Z, Liu X, Jiang L, Yu M, Xu N, Wu F, Dang L, Zhou H, et al: Upper cervical spine reconstruction using customized 3D-printed vertebral body in 9 patients with primary tumors involving C2. Ann Transl Med. 8:3322020. View Article : Google Scholar : PubMed/NCBI
9	Osborn VW, Lee A and Yamada Y: Stereotactic body radiation therapy for spinal malignancies. Technol Cancer Res Treat. 17:15330338188023042018. View Article : Google Scholar : PubMed/NCBI
10	Ladra MM, Szymonifka JD, Mahajan A, Friedmann AM, Yong Yeap B, Goebel CP, MacDonald SM, Grosshans DR, Rodriguez-Galindo C, Marcus KJ, et al: Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma. J Clin Oncol. 32:3762–3770. 2014. View Article : Google Scholar : PubMed/NCBI
11	Gong Y, Xu L, Zhuang H, Jiang L, Wei F, Liu Z, Li Y, Yu M, Ni K and Liu X: Efficacy and safety of different fractions in stereotactic body radiotherapy for spinal metastases: A systematic review. Cancer Med. 8:6176–6184. 2019. View Article : Google Scholar : PubMed/NCBI
12	Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, et al: Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's oncology group study D9803. J Clin Oncol. 27:5182–5188. 2009. View Article : Google Scholar : PubMed/NCBI
13	Arndt CA, Hawkins DS, Meyer WH, Sencer SF, Neglia JP and Anderson JR: Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: A report from the children's oncology group. Pediatr Blood Cancer. 50:33–36. 2008. View Article : Google Scholar : PubMed/NCBI
14	Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan A, Parham DM, Cripe TP, Anderson JR, Meyer WH and Hawkins DS: Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the soft tissue sarcoma committee of the children's oncology group. Cancer. 123:2368–2375. 2017. View Article : Google Scholar : PubMed/NCBI
15	Dumont SN, Araujo DM, Munsell MF, Salganick JA, Dumont AG, Raymond KA, Linassier C, Patel S, Benjamin RS and Trent JC: Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients. Cancer Med. 2:553–563. 2013. View Article : Google Scholar : PubMed/NCBI
16	Gupta AA, Anderson JR, Pappo AS, Spunt SL, Dasgupta R, Indelicato DJ and Hawkins DS: Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: A report from the children's oncology group soft tissue sarcoma committee. Cancer. 118:1130–1137. 2012. View Article : Google Scholar : PubMed/NCBI
17	Bisogno G, Jenney M, Bergeron C, GallegoMelcón S, Ferrari A, Oberlin O, Carli M, Stevens M, Kelsey A, De Paoli A, et al: Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): A multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol. 19:1061–1071. 2018. View Article : Google Scholar : PubMed/NCBI
18	Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, Donaldson SS, Hayes-Jordan A, Mascarenhas L, McCarville MB, et al: Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: A report from the children's oncology group. J Clin Oncol. 36:2770–2777. 2018. View Article : Google Scholar : PubMed/NCBI
19	Hawkins DS, Gupta AA and Rudzinski ER: What is new in the biology and treatment of pediatric rhabdomyosarcoma? Curr Opin Pediatr. 26:50–56. 2014. View Article : Google Scholar : PubMed/NCBI
20	Weitao Y, Fangxing W, Qiqing C and Jiaqiang W: Efficacy and safety of apatinib in advanced sarcoma: An open-label, nonrandomized, single-center study of 45 patients. Anticancer Drugs. 30:e07782019. View Article : Google Scholar : PubMed/NCBI
21	van Erp AEM, Versleijen-Jonkers YMH, van der Graaf WTA and Fleuren EDG: Targeted therapy-based combination treatment in rhabdomyosarcoma. Mol Cancer Ther. 17:1365–1380. 2018. View Article : Google Scholar : PubMed/NCBI